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PODIUM SESSION I: RESEARCH ON DATABASE METHODS
DB1
DEVELOPMENT AND VALIDATION OF A MODEL TO PREDICT 
VIROLOGIC FAILURE USING ADMINISTRATIVE CLAIMS
Juday T1, Jing Y1, Chang E2, Broder M2
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Partnership for Health Analytic Research, LLC, 
Beverly Hills, CA, USA
OBJECTIVES: When studying HIV infection, administrative claims databases can 
provide information on treatment and cost for large numbers of patients but most do 
not contain laboratory test results, making it impossible to know when a change in 
antiretroviral treatment (ART) was due to virologic failure. Our objective was to 
develop and validate a model for identifying patients in a claims database who 
switched ART due to virologic failure. METHODS: We identiﬁed three databases of 
adult HIV-positive patients who switched ART regimens between January 1, 2003 
and March 31, 2008. The HIV Insight clinical registry was used to develop a logistic 
regression model incorporating demographics, regimen characteristics, and other inde-
pendent variables to estimate the odds of virologic failure. Next, the subset of the 
Ingenix i3 LabRx health insurance claims database with HIV viral load test results 
(claims/lab database) was used to validate the model. The model was then used to 
estimate the proportion of patients with virologic failure in the full Ingenix i3 LabRx 
claims database (claims database). RESULTS: There were 1,691 patients with ART 
switches in HIV Insight; 1,073 in the claims/lab database, and 3,954 in the claims 
database. The base model (main effects only) had good discriminatory ability (c = 
0.875); but poor overall model ﬁt (Hosmer Lemeshow test, p < 0.001). Adding three 
signiﬁcant two-way interaction terms improved ﬁt (p = 0.8692) and discriminatory 
ability (c = 0.885). When the ﬁnal model was applied to the claims/lab database, it 
predicted 18.9% of patients would have virologic failure; the actual proportion was 
18.6%. CONCLUSIONS: We developed and validated a model that could be used in 
administrative claims to predict the proportion of ART switches due to virologic 
failure. Health plans may use this model to identify treatments with rising rates of 
virologic failure and to examine costs related to such failure.
DB2
EVALUATION OF AGREEMENT BETWEEN INTERNET-BASED 
SELF- AND PROXY-REPORTED HEALTH CARE UTILIZATION AND 
ADMINISTRATIVE HEALTH CARE CLAIMS
Palmer L1, Johnston SS1, Rousculp M2, Nichol KL3, Mahadevia PJ2
1Thomson Reuters, Washington, DC, USA, 2MedImmune, Gaithersburg, MD, USA, 
3University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: Mode of survey administration is an important determinant of the 
validity/accuracy of self-reported, health care utilization (HCRU). While Internet-
based surveys are becoming more common, little is known about agreement between 
administrative claims data and Internet-based survey self- and proxy-reported HCRU. 
This analysis evaluated the level of agreement of self- and proxy-reported HCRU as 
recorded through an Internet-based survey as compared to administrative claims-based 
HCRU data from three large self-insured U.S. employers. METHODS: Monthly 
Internet-based surveys of employees (n = 2,298) in the Child and Household Inﬂuenza-
Illness and Employee Function Study were captured 11/07–5/08. The survey captured 
data on the presence and number of visits to hospitals, emergency departments, urgent 
care centers and ofﬁce visits for employees’ care and for household member (HHM) 
care (n = 6,884). Administrative claims from the Marketscan® Databases were 
assessed during the same time period and evaluated relative to the survey-based HCRU 
metrics. Only data for individuals with employer-sponsored health care coverage and 
who could be linked to the claims data using via direct matching was included (n = 
5,718, 62%). The Kappa (κ) statistic was used to evaluate visit concordance and 
correlation statistics were used to describe frequency consistency. RESULTS: There 
was moderate to substantial visit presence and frequency agreement between survey-
based and claims-based HCRU for all service categories. Percent agreement for pres-
ence of a particular service ranged from 99.2% (inpatient stay, κ = 0.71) to 76.4% 
(outpatient visits, κ = 0.52). The correlation in the survey-based and claims-based visit 
frequency for inpatient, emergency department, urgent care center and outpatient visits 
was 0.59, 0.66, 0.42 and 0.61 respectively (all p < 0.001). Visit presence and frequency 
agreement was similar for self- and proxy-reported HCRU. CONCLUSIONS: Relative 
to previously published HCRU metrics elicited from paper and telephony survey 
methods, this study’s agreement values suggest that Internet-based surveys are an 
effective method to collect self- and proxy-reported HCRU.
DB3
MUCH ADO ABOUT THE LACK OF SOCIO-ECONOMIC COVARIATES IN 
ADMINISTRATIVE CLAIMS DATA
Borah B
Mayo Clinic, Rochester, MN, USA
OBJECTIVES: Administrative claims data from managed care plans are often used to 
assess health care utilization and cost. However, a major criticism against the use of 
claims data is that they often lack socio-economic-status (SES) information including 
race, years of education, marital status and household income. Therefore, claims-based 
estimates of utilization and cost measures may be biased. Using Medical Expenditures 
Panel Survey (MEPS), this paper shows that the SES factors may not have signiﬁcant 
bearing on the predicted utilization and cost measures. METHODS: The 2007 
MEPS data were used for this study. In order to make the study sample resemble a 
typical sample from claims data from a managed care plan, MEPS patients 
aged between 18 and 65 years enrolled in a managed care plan throughout 2007 
were included in the ﬁnal sample. Overall and pharmacy costs were analyzed using 
generalized linear modeling (GLM) with gamma distribution and log link while the 
number of ofﬁce and outpatient visits were modeled using GLM with Poisson distribu-
tion and log link. Each regression was run with and without the four SES variables, 
and the resulting predicted values were compared. RESULTS: The predicted number 
of ofﬁce and outpatient visits with SES covariates in the GLM regression equation 
were 2.81(SD = 1.92) and 0.43(SD = 0.65), and without SES covariates were 2.83(SD 
= 1.91) and 0.41(SD = 0.61). Similarly, the predicted pharmacy and total health care 
cost with SES covariates were $897(SD = $1,562) and $3,990(SD = $4,697), and 
without SES covariates were $854(SD = $1,334) and $4,101(SD = $4,633). Thus, 
predicted utilization and cost measures with or without the SES variables in the cor-
responding GLM regression were not statistically different. CONCLUSIONS: Our 
results reject the hypothesis that the lack of SES covariates in claims data might result 
in biased estimates of utilization and cost. Further investigation is warranted to check 
the robustness of the model speciﬁcations for utilization and cost.
DB4
ACCOUNTING FOR THE RELATIONSHIP BETWEEN PER DIEM COST 
AND LOS WHEN ESTIMATING HOSPITALIZATION COSTS
Stolar M1, Hu MY2, Ishak K3, Wang Y2, Williams GC2, Ferguson J2, Getsios D4, Alvarez P1
1United BioSource Corporation, Lexington, MA, USA, 2The Medicines Company, Parsippany, 
NJ, USA, 3United BioSource Corporation, Dorval, QC, Canada, 4United BioSource 
Corporation, Halifax, NS, Canada
OBJECTIVES: Hospitalization costs in trials are often derived using observed lengths 
of stay (LOS) and ﬁxed per diem costs obtained from supplemental data sources. This 
approach assumes per diem costs are independent of LOS, which is generally not the 
case. We sought to develop an approach that accounts for this relationship to obtain 
more accurate cost estimates. METHODS: To examine the association between peri-
operative blood pressure control and hospitalization costs for coronary artery bypass 
graft (CABG), valve surgery or combined surgeries, data from the Massachusetts Acute 
Hospital Case Mix Database for 2005–2007 were used to derive LOS-speciﬁc per 
diem costs. Regression analyses were carried out to model this relationship, allowing 
for non-linear functional forms. Costs were log-transformed to account for their 
skewed distributions. Exploratory analyses were carried out to identify suitable 
parameterizations and candidate models were compared using goodness-of-ﬁt statis-
tics. Complications occurring during hospitalization were included as predictors of 
per diem costs with a possible interaction with LOS. For illustrative purposes we 
present results for patients undergoing CABG. RESULTS: The Massachusetts database 
yielded 10,601 patients undergoing CABG. Mean ± SD LOS was 9.47 ± 5.86 days 
and per diem cost was $6,241 ± $3,019. Per diem costs varied across different com-
plications and LOS. Per diem costs were highest for patients who died in-hospital and 
those with multiple complications. Per diem costs were high for short LOS, then 
declined steadily to LOS of 14 days, and were relatively constant thereafter, showing 
a linear relationship between log per diem costs and log LOS. This model had consider-
ably better ﬁt compared to one that assumed a single per diem cost (Akaike Informa-
tion Criterion 7,825 vs. 10,440, respectively). CONCLUSIONS: Mean per diem costs 
depend highly on the LOS of the hospitalization. Accounting for the relationship 
between per diem cost and LOS yields better estimates of costs and subsequent 
inferences.
PODIUM SESSION I: HEALTH CARE EXPENDITURES STUDIES
HE1
COST-EFFECTIVENESS OF 1ST LINE CHEMOTHERAPY REGIMENS IN 
THE TREATMENT OF NON-SMALL CELL LUNG CANCER AMONG 
PATIENTS RECEIVING CARE IN THE OUTPATIENT COMMUNITY 
SETTING
Hoverman JR1, Pohl G2, Gruschkus SK3, Marciniak M2, Forsyth M3, Peltz G2
1Texas Oncology, Dallas, TX, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 
3Healthcare Informatics, The Woodlands, TX, USA
OBJECTIVES: To evaluate the incremental cost-effectiveness of combination peme-
trexed/platinum chemotherapy relative to other common chemotherapy regimens for 
1st line treatment of non-small cell lung cancer (NSCLC). METHODS: NSCLC 
patients initiating 1st line chemotherapy (pemetrexed/platinum (P/P); carboplatin/pacli-
taxel + bevacizumab (C/P + B); or carboplatin/paclitaxel (C/P)) from July 1, 2006–June 
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30, 2008 within a large nationwide network of outpatient oncology clinics were 
studied using US Oncology’s iKnowMed EMR. Costs included only those incurred 
within the network of outpatient oncology clinics and were derived using Medicare 
reimbursement rates. Patients were matched across regimens on key confounding 
factors at initiation of treatment: age, stage at diagnosis, ECOG performance status, 
and comorbidity index. A variable N:M matching ratio was used. Patients were fol-
lowed through June 30, 2009. A 95% conﬁdence intervals were estimated by boot-
strapping (2500 samples) the within-cell differences in cost and time to progression 
(TTP) of matched patients. RESULTS: A total of 1194 patients were identiﬁed: 48 
received P/P, 279 received C/P + B, and 867 received C/P. We found that P/P exhibited 
dominance vs. C/P + B, with higher effectiveness (mean difference in TTP = 1.7 
months; CI = 1.1- 2.3 months) and lower cost (mean cost difference = −$22,890; CI 
= $−25,445–$−20,335). Compared to C/P, P/P had higher effectiveness (mean differ-
ence in TTP = 2.0 months; CI = 1.7- 2.4 months) but also higher costs (mean cost 
difference = $12,603; CI = $11,579–$13,667) with an incremental cost effectiveness 
of $6,335/progression-free month (CI = 5,432–7,404). CONCLUSIONS: This study 
suggests that P/P may be a cost-effective 1st line NSCLC treatment in the outpatient 
community setting. Costs differences were substantial by regimen while differences in 
TTP were relatively small from a clinical perspective. While this preliminary study 
utilized conservative analytic methods and controlled for several key confounding 
factors, future large studies should attempt to further address selection bias and 
residual confounding.
HE2
HEALTH CARE COSTS OF METASTATIC SQUAMOUS CELL 
CARCINOMA OF HEAD AND NECK—FINDINGS FROM LINKED 
SEER-MEDICARE DATA
Parthan A1, Kulakodlu M2, Deﬂin M1, Taylor D3, Barber B4, Zhao Z4
1i3 Innovus, San Francisco, CA, USA, 2i3 Innovus, Eden Prairie, MN, USA, 3i3 Innovus, 
Medford, MA, USA, 4Amgen, Inc, Thousand Oaks, CA, USA
OBJECTIVES: To estimate health care utilization and costs for patients with incident 
metastatic squamous cell carcinoma of head and neck (mSCCHN). METHODS: 
Incident mSCCHN patients between 1993 and 2005 were identiﬁed in the SEER-
Medicare database using ICD-O codes for primary site and histology with a “distant” 
tumor in the SEER staging variable. Individuals 65 years or older at the time of 
diagnosis, with at least 12 months of data preceding initial diagnosis were included. 
The index date was deﬁned as the date of diagnosis; subjects were followed from 30 
days prior to the index date until death or the end of Medicare claims data (December 
31, 2007), whichever occurred ﬁrst. Chemotherapy use was identiﬁed using HCPCS 
codes. Resource use and health care costs were estimated using the person-years 
approach to account for patients having different lengths of follow-up. RESULTS: A 
total of 1420 subjects with mSCCHN were included in this analysis. Mean age was 
74 (SD 6.7) years and 70% were males. Mean Charlson comorbidity score without 
malignancy was 1.4 (SD 1.6) and mean duration of follow-up was 30 months (SD 
33). Forty-eight percent of patients received chemotherapy. Carboplatin (18%) was 
the most commonly used agent followed by paclitaxel (13%) and cisplatin (11%). 
The mean number of visits per patient per year was 9.7 (SD 10.7) for outpatient care 
and 2.9 (SD 3.7) for inpatient care. Average annual inpatient days per patient were 
31.4 days (SD 51.1). About 40% of the patients received hospice care. Mean total 
annual health care costs per patient were $155,307, cost of outpatient care constituted 
51% and inpatient care 34%. CONCLUSIONS: Inpatient and outpatient costs are 
the key drivers of total health care costs for patients with mSCCHN.
HE3
CAN INNOVATION BE REWARDED WITH THE APPLICATION OF RIGID 
COST-EFFECTIVENESS THRESHOLDS? THE HER2+VE BREAST CANCER 
CASE STUDY
Ray J, Cirrincione A
F. Hoffmann-La Roche Ltd., Basel, Switzerland
OBJECTIVES: Trastuzumab (Tras) in combination with chemotherapy is the current 
treatment standard in patients with early and metastatic breast cancer (BC) who are 
HER2 positive (HER2+). Any regimen under development will have to be compared 
to Tras both in pivotal clinical trials and during economic assessment. This study raises 
important policy questions by estimating the feasibility of demonstrating cost-effec-
tiveness (CE) against conventional UK NICE thresholds (£ 20–30,000/QALY gained) 
for new regimens developed in different lines of treatment for HER2+ BC and incen-
tives for development where rigid thresholds are applied. METHODS: Three CE 
models were developed using rates of disease progression, survival and efﬁcacy data 
from 3 Tras clinical trials: HERA for adjuvant, M77001 for 1st-line metastatic and 
GBG-26 for 2nd-line metastatic BC. Isometrics curves were generated for each model 
whereby each point on the curve corresponded to where the progression-free & overall 
survival hazard ratios and increase in total costs for the new treatment versus Tras 
was estimated to result in an ICER of £ 30’000/QALY. Costs and utility values were 
based on published literature from the UK-NHS perspective. RESULTS: Assuming a 
5-year duration of efﬁcacy in early BC (PFS hazard ratio of 0.75), the model estimated 
that a new treatment could be considered cost-effective with medication acquisition 
costs 81% above Tras. In the metastatic setting (1st and 2nd-line), similar incremental 
improvements in efﬁcacy, for the OS and PFS hazard ratios over 5 years, suggests that 
a new regimen could not have medication acquisition costs more than 6–7% above 
Tras. CONCLUSIONS: Given current treatment costs of the background regimen, it 
is unlikely that any new combination regimen will be cost-effective using UK thresh-
olds. Results were not sensitive to the magnitude of the incremental survival beneﬁt 
due to the high correlation between treatment beneﬁt, treatment duration (until cancer 
progression), and overall treatment costs.
HE4
CHARACTERIZATION OF FREQUENT HOSPITAL EMERGENCY 
DEPARTMENT (ED) USE BY UN- OR UNDERINSURED PERSONS
Khurshid A1, Strassels S2
1Integrated Care Collaboration, Austin, TX, USA, 2University of Texas at Austin, Austin, 
TX, USA
OBJECTIVES: ED use for non-emergencies contributes to crowding, increased health 
care costs, and, potentially, poor clinical outcomes. Efforts to decrease inappropriate 
ED use have focused on insured individuals. The purpose of this retrospective cohort 
study was to characterize frequent ED use among un- and underinsured individuals 
in central Texas. METHODS: Data were obtained from the ICare system, which 
includes information for > 800,000 individuals and > 5 million encounters within 24 
Central Texas health care providers who arrange for or provide care for uninsured or 
underinsured individuals. Persons who received care from an ICare-participating orga-
nization during calendar year 2007 were included in these analyses. Frequent ED use 
was deﬁned as at least 6 ED visits within either a calendar quarter or any contiguous 
three-month period. Linear regression was used to estimate the relation between 
patient characteristics and total ED visits among frequent users. RESULTS: There 
were 216,364 ED visits in 2007; 128,538 individuals had at least 1 ED visit and 0.7% 
(n = 892) were considered frequent ED users. Frequent users were mainly female 
(55.6%), and Caucasian (55.8%). Hispanics and African-Americans accounted for 
14.2% and 17.3% of frequent users, respectively. The regression model accounted for 
12.1% of variability in the outcome. Total clinic visits (beta = 0.05, p 0.037, 95% CI 
0.003–0.094), inpatient admissions (beta = 1.35, p < 0.001, 95% CI 0.976–1.716) 
and having any mental health diagnosis in any ED visit (beta = 3.278, p < 0.001. 95% 
CI 2.060–4.496) were positively and statistically signiﬁcantly associated with the 
number of ED visits among frequent users, after adjusting for age, sex, and race. 
CONCLUSIONS: In 2007, frequent users accounted for < 1% of ED users, and 5.4% 
of total ED use. A study of these frequent users may help identify opportunities for 
intervention to help underlying causes for these frequent visits.
PODIUM SESSION I: HEALTH TECHNOLOGY ASSESSMENT STUDIES
HT1
COMPARATIVE-EFFECTIVENESS VERSUS COST-EFFECTIVENESS: A 
COMPARISON OF THE FRENCH AND SCOTTISH APPROACHES TO 
SINGLE TECHNOLOGY ASSESSMENT (STA)
Bending MW1, Hutton J1, McGrath C2
1University of York, York, UK, 2Pﬁzer, Walton on the Hill, Surrey, UK
OBJECTIVES: To compare the pharmaceutical STA guidance advice of Haute Autorité 
de santé (HAS) which appraises clinical efﬁcacy/safety against the Scottish Medicines 
Consortium (SMC) in which appraisal includes both clinical and cost-effectiveness. 
METHODS: All English translated advice were downloaded from the HAS website 
resulting in 78 transparency committee opinions for between 2005 and 2009. These 
were matched with SMC advice, resulting in 39 matched drugs. A comparison between 
drug advice, the clinical evidence through identiﬁcation of trials on the CENTRAL 
database of the Cochrane library and a statistical analysis was performed on improve-
ment in medical beneﬁt (ASMR) supplied by HAS and the cost-utility estimates (CQG) 
of the SMC. RESULTS: The HAS and SMC had the same advice in 14/39 (36%) of the 
drug comparisons. The average number of trials included were 2 trials in HAS advice 
and 1.8 trials in SMC advice with more comprehensive detail on the efﬁcacy in HAS 
advice. Each matched comparison had at least one common trial and 30% of guidance 
included different additional trials. The correlation between the medical improvement 
provided by HAS and the SMC CQG were analysed and show that for those treatments 
considered cost saving by the SMC the ASMR was on average 4.6. The CQG for 
£0-£10,000 had an average ASMR; 3.6, £10,000-£20,000; 2.8, £20,000-£30,000; 3.1, 
and £30,000+; 3.4, showing little correlation between ASMR and CQG. CONCLU-
SIONS: The differences in guidance advice reﬂect the countries different HTA pro-
cesses, interpretation of clinical efﬁcacy and approaches to economics. HAS advice 
provided more detailed information on the clinical efﬁcacy in comparison to SMC for 
these drugs. The SMC presented formal analysis of cost-effectiveness in comparison to 
France where economic issues are considered by the economic committee and not 
reported. The transparency committee implicitly uses economics as the choice of ASMR 
inﬂuences pricing decisions and the cost-effectiveness of treatments.
HT2
VARIABILITY IN UTILIZATION OF INNOVATIVE DRUGS IN EUROPE AS 
A RESULT OF HEALTH TECHNOLOGY ASSESSMENT AND FUNDING 
PROCEDURES: EXAMPLES OF TRASTUZUMAB AND CETUXIMAB
Toumi M1, Misset JL2, Cristeau O1, Krukowski L3, Aballea S4, Lamure M5
1University Claude Bernard Lyon 1, Lyon, France, 2Hopital Saint Louis, Paris, France, 
3Synovate, London, UK, 4CREATIV-CEUTICAL, Paris, France, 5University Claude Bernard 
Lyon 1, Paris, France
OBJECTIVES: Prices of recently launched monoclonal antibodies are high and their 
accessibility differs across Europe. Trastuzumab (TRZ) was recommended by payers 
for early and advanced breast cancer (BC) in Europe, with differences in the process 
and timelines of recommendations. Cetuximab (CTX) for metastatic colorectal cancer 
